Health News
Health News

Cancer Vaccines Show Promise, But Integration Into Care Remains a Challenge

By Claire Ashworth ·

INTerpath-001 Trial Results

The encouraging results show that adding a novel mechanism to a checkpoint inhibitor significantly reduces recurrence and distant metastases.

Biological Rationale and Limitations

In the INTerpath-001 trial, 1,137 patients with resected stage IIB–IV melanoma were randomized. Data presented at ESMO showed 82.2% two-year recurrence-free survival for patients receiving the autogene mRNA vaccine (intismeran autogene) combined with pembrolizumab (Keytruda). This compared to 70% for the control group receiving placebo plus pembrolizumab. The absolute difference was 12.2 percentage points, with a hazard ratio of 0.58 (95% CI 0.45-0.75). At a median follow-up of 24.6 months, an overall survival benefit had not yet been demonstrated.

Preventing recurrence has clear clinical value, saving patients from additional treatments and complications. Not all patients benefited, and these results do not establish efficacy in other cancer types. The biological rationale for intismeran autogene is compelling: personalized vaccines encode tumor-specific neoantigens, which are processed and presented by antigen-presenting cells, priming and expanding tumor-reactive T cells. PD-1 blockade joins this response, reducing inhibitory signaling that limits T-cell activity. Thus, vaccination can broaden tumor-directed immunity, while checkpoint inhibition supports its function. Although INTerpath-001 demonstrates the benefit of adding vaccination to pembrolizumab, the absence of a vaccination-only arm prevents formal establishment of synergy.

Neoadjuvant Immunotherapy Context

This approach integrates tumor sequencing, computational antigen selection, mRNA delivery, and immunotherapy. However, a predicted neoantigen is not necessarily an effective immune target. Translational studies must clarify which responses control cancer clones responsible for recurrence. The vaccine discussion must also consider progress in neoadjuvant immunotherapy. In SWOG S1801, starting pembrolizumab before surgery improved event-free survival compared to administration only after surgery. In NADINA, the neoadjuvant combination of nivolumab and ipilimumab, followed by surgery and response-based adjuvant therapy, improved event-free survival compared to surgery followed by nivolumab (Opdivo).

Sequencing and Patient Selection

These advances make treatment sequencing a central research question. Can vaccination improve outcomes after neoadjuvant immunotherapy? Patients without a major pathological response may have the greatest need for this treatment. Conversely, patients with a major response might avoid additional treatments. The INTerpath-001 study does not answer these questions. Cross-study comparisons are insufficient because populations, endpoints, and therapeutic strategies differ. The neoadjuvant question is especially relevant for patients with clinically visible, resectable stage III disease; it should not overshadow vaccination results for other patients in the study.

We need studies that integrate therapeutic advances, rather than simply accumulating adjuvant treatments. The presence of residual disease after checkpoint inhibition does not necessarily imply sensitivity to vaccination. This hypothesis requires testing. Beyond melanoma, our optimism must remain moderate, guided by evidence. Tumors differ in antigen availability, antigen presentation, immune infiltration, and immune suppression mechanisms. However, initial results justify investigation and enthusiasm. A phase I study for pancreatic cancer demonstrated persistent T-cell responses induced by the vaccine in some patients receiving a personalized mRNA vaccine alongside atezolizumab and chemotherapy. Patients with immune response had longer recurrence-free survival than those without.

Future Directions and Other Cancers

This establishes biological activity, but does not prove that vaccination improves outcomes in pancreatic cancer. The study was small, lacked a randomized control group, and compared patients based on immune response. A randomized study is underway for more rigorous evaluation of the combination. Patient selection deserves the same discipline. Pathological response and circulating tumor DNA are attractive candidates for refining postoperative decisions. However, identifying patients at higher risk of recurrence is different from identifying those most sensitive to vaccination. Biomarker-guided therapeutic strategies require prospective evaluation. Treatment delivery is also a clinical endpoint in real-world practice.